Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Samambaia Investimentos is a Brazilian private investment firm and family office controlled by billionaire José João Abdalla Filho. The firm is a significant institutional investor in the global life sciences and healthcare sectors, maintaining substantial positions in major biotechnology companies including Atai Life Sciences, Compass Pathways, and Centessa Pharmaceuticals. Domestically, Samambaia is a principal shareholder in Hapvida NotreDame Intermédica, the largest managed care and hospital operator in Brazil. The firm is characterized by its long-term value-oriented investment strategy and its role as a key financial backer for innovative platforms in mental health and oncology. While it does not conduct internal R&D or maintain a drug pipeline, its capital is instrumental in the growth of several high-profile clinical-stage biotechs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Samambaia Investments.